Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
A group of 195 patients with histologically proven adenocarcinoma of the prostate limited to pelvis were treated with definitive irradiation between 1967 and December 1976. In 42 patients with Stage B adenocarcinoma, the tumor free actuarial five year survival was 80%; for 141 with Stage C it was 56%; there were no long term survivors in 12 patients with Stage D1. The pelvic failure rate was 7% in Stage B, 17% in Stage C and 25% in Stage D1. Histological differentiation of the tumor had no significant impact in survival of patients with Stage B. However, in Stage C, patients with well or moderately differentiated tumor had a five year survival of 70% in contrast to 25% in those with poorly differentiated lesions. In this group of patients 60% of the failures resulted from distant metastasis. In Stage C, 38% of the patients who were treated with doses between 5500 and 6000 rad developed pelvic failures, as opposed to 20% of those treated with a mean dose of 6500 rad and 12% in patients receiving 7000 rad or greater dose. The addition of hormonal therapy, usually castration and diethylstilbestral, did not significantly affect the prognosis of patients with Stage B or C. Major complications of therapy occurred in 11% of the patients. The most common problem was urinary incontinence.
Research Organization:
Washington Univ. School of Medicine, St. Louis, MO
OSTI ID:
7078837
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 6:5; ISSN IOBPD
Country of Publication:
United States
Language:
English